ArticleAIDS (London, England)2026
Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1.
Article in AIDS (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe Month (M) 24 outcomes following switch to cabotegravir plus rilpivirine long-acting (CAB+RPV LA) in the CARLOS study.
designA noninterventional, 3-year, multicenter study.
methodsM24 effectiveness outcomes included virologic suppression (HIV-1 RNA <50 c/ml), nonresponse (HIV-1 RNA ≥50 c/ml), and protocol-defined virologic failure (PDVF; two consecutive HIV-1 RNA ≥200 c/ml, or a single HIV-1 RNA ≥200 c/ml followed by treatment discontinuation for any reason). Additional outcomes included dosing window adherence and patient-reported outcomes.
resultsIn total, 351 people with HIV were included in the analysis at M24. Overall, 94% ( n = 3464/3676) of CAB+RPV LA injections were administered before or within the ±7-day dosing window; 6% ( n = 212/3676) occurred late. At M24, 77% ( n = 272/351) of participants maintained virologic suppression, 20% ( n = 70/351) discontinued or had no data in window with last observation carried forward <50 c/ml, 0.6% ( n = 2/351) had a single HIV-1 RNA ≥50 c/mL, and 2% ( n = 7/351) had PDVF. There was a low rate of discontinuation due to injection site reactions. A statistically significant increase in treatment satisfaction total score was observed from baseline to M24 (mean/maximum score [standard deviation], 55.0/66 [10.0]) and 61.0/66 [7.1], respectively; mean change, +6.0; P < 0.001; n = 233), meeting the threshold for minimum clinically important difference.
conclusionIn this real-world study, CAB+RPV LA maintained high rates of virologic suppression, was well tolerated, and led to increased treatment satisfaction through 24 months following switch. These data reinforce the findings of the Phase 3/3b CAB+RPV LA program and support the continued use of CAB+RPV LA in routine clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.